• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2018 年加拿大《大麻法案》的影响:医用和非医用大麻的监管是否应该有所不同?

Implications of the 2018 Canadian Cannabis Act: Should regulation differ for medicinal and non-medicinal cannabis use?⋆.

机构信息

University of Ottawa, Faculty of Law (Common Law), Fauteux Hall, 57 Louis Pasteur St., Ottawa, ON K1N6N5, Canada.

出版信息

Health Policy. 2021 Jan;125(1):12-16. doi: 10.1016/j.healthpol.2020.10.016. Epub 2020 Nov 11.

DOI:10.1016/j.healthpol.2020.10.016
PMID:33208249
Abstract

The regulatory framework for access to medical cannabis has been established in Canada since 2001, with the number of patients seeking access growing substantially over the years. With the novel enactment of the Cannabis Act in October 2018, Canada now maintains two distinct mechanisms for accessing cannabis - one for medical cannabis and the other for non-medical cannabis. With two regulatory access mechanisms in place, questions have arisen in the country as to the necessity of maintaining regulatory separation and the integrity of the medical access framework. A single framework would remove the gate-keeping function that the medical profession currently holds, streamlining processes and simplifying the current regulatory landscape. This approach has been advocated for by the Canadian Medical Association, despite objections from multiple stakeholders. Critical questions arise should the medical access framework be dissolved into a single, non medical-based regulatory framework. Insurance coverage, control mechanisms, market incentives, and patient obligations represent some examples of these issues. This paper will expand upon these considerations and highlight why maintaining two separate access mechanismss best serves the Canadian public. As medicinal cannabis continues to be liberated in international jurisdictions, this paper can help to illuminate the current status of medical cannabis in Canada, and provide insights to those from other countries on our current approach and domestic challenges.

摘要

自 2001 年以来,加拿大已经建立了医疗大麻准入的监管框架,寻求准入的患者人数多年来大幅增加。随着 2018 年 10 月《大麻法》的新颁布,加拿大现在为获取大麻维持着两种截然不同的机制——一种是医疗用大麻,另一种是非医用大麻。有了这两个监管准入机制,加拿大国内出现了一些问题,例如是否有必要维持监管分离和医疗准入框架的完整性。一个单一的框架将消除医疗行业目前所拥有的把关职能,简化流程,简化当前的监管格局。尽管遭到多个利益相关者的反对,但加拿大医学会还是倡导了这一做法。如果将医疗准入框架融入一个单一的、非医疗为基础的监管框架,就会产生一些关键性问题。保险覆盖范围、控制机制、市场激励措施和患者义务就是其中的一些例子。本文将对这些问题进行扩展,并强调为什么维持两个独立的准入机制最符合加拿大公众的利益。随着药用大麻在国际司法管辖区继续合法化,本文可以帮助阐明加拿大目前医用大麻的现状,并为其他国家提供有关我们目前方法和国内挑战的见解。

相似文献

1
Implications of the 2018 Canadian Cannabis Act: Should regulation differ for medicinal and non-medicinal cannabis use?⋆.2018 年加拿大《大麻法案》的影响:医用和非医用大麻的监管是否应该有所不同?
Health Policy. 2021 Jan;125(1):12-16. doi: 10.1016/j.healthpol.2020.10.016. Epub 2020 Nov 11.
2
Medical use of cannabis products: Lessons to be learned from Israel and Canada.大麻产品的医学用途:从以色列和加拿大汲取的经验教训。
Schmerz. 2016 Feb;30(1):3-13. doi: 10.1007/s00482-015-0083-4.
3
Coverage of medical cannabis by Canadian news media: Ethics, access, and policy.加拿大新闻媒体对医用大麻的报道:伦理、准入和政策。
Int J Drug Policy. 2021 Nov;97:103361. doi: 10.1016/j.drugpo.2021.103361. Epub 2021 Jul 10.
4
Medical cannabis in supportive cancer care: lessons from Canada.支持性癌症护理中的医用大麻:来自加拿大的经验教训。
Support Care Cancer. 2020 Jul;28(7):2999-3001. doi: 10.1007/s00520-020-05403-2. Epub 2020 Mar 14.
5
Mapping regulatory models for medicinal cannabis: a matrix of options.绘制药用大麻的监管模式:选项矩阵
Aust Health Rev. 2018 Aug;42(4):403-411. doi: 10.1071/AH16257.
6
The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018.2018 年,加拿大《大麻法案》使休闲大麻合法化并对其进行监管。
Health Policy. 2018 Mar;122(3):205-209. doi: 10.1016/j.healthpol.2018.01.009. Epub 2018 Jan 31.
7
Medical Marijuana programs: implications for cannabis control policy--observations from Canada.医用大麻项目:对大麻管制政策的影响——来自加拿大的观察。
Int J Drug Policy. 2015 Jan;26(1):15-9. doi: 10.1016/j.drugpo.2014.09.007. Epub 2014 Sep 22.
8
Medicinal cannabis and driving: the intersection of health and road safety policy.药用大麻与驾驶:健康与道路安全政策的交叉点
Int J Drug Policy. 2021 Nov;97:103307. doi: 10.1016/j.drugpo.2021.103307. Epub 2021 Jun 6.
9
MEDICINAL CANNABIS LAW REFORM: LESSONS FROM CANADIAN LITIGATION.药用大麻法律改革:加拿大诉讼的经验教训
J Law Med. 2015 Jun;22(4):719-38.
10
The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts".《魔鬼在细节中!根据公共卫生标准规范加拿大的大麻使用》评“加拿大大麻合法化和监管:潜在经济、社会和健康影响的综述”。
Int J Health Policy Manag. 2017 Mar 1;6(3):173-176. doi: 10.15171/ijhpm.2016.114.

引用本文的文献

1
Trema micranthum (L.) Blume as a new source of cannabinoids.微花藤(L.)Blume 作为大麻素的新来源。
Sci Rep. 2024 Nov 28;14(1):29620. doi: 10.1038/s41598-024-80857-6.
2
Canada's Recreational Cannabis Legalization and Medical Cannabis Patient Activity, 2017-2022.加拿大休闲大麻合法化与医疗大麻患者活动:2017-2022 年
Am J Public Health. 2024 Nov;114(S8):S673-S680. doi: 10.2105/AJPH.2024.307721. Epub 2024 Oct 3.
3
Clinician views on and ethics priorities for authorizing medical cannabis in the care of children and youth in Canada: a qualitative study.
加拿大临床医生对在儿童和青少年护理中批准医用大麻的看法及伦理优先事项:一项定性研究
CMAJ Open. 2022 Mar 15;10(1):E196-E202. doi: 10.9778/cmajo.20210239. Print 2022 Jan-Mar.